阿哌沙班:临床药代动力学与药效学综述
阿哌沙班为口服直接Xa因子抑制剂,抑制游离型与血栓结合型Xa因子,获批用于非瓣膜性房颤卒中预防、髋膝关节置换术后血栓预防及深静脉血栓/肺栓塞治疗与复发预防。本综述汇总其药代动力学、药效学、生物药剂学与药物相互作用特征及群体药代动力学分析。
要点
- 口服绝对生物利用度约50%,食物无临床意义影响,10mg及以下剂量暴露呈剂量比例增加。
- 口服后3-4小时达峰浓度,半衰期约12小时,约27%的总清除经肾排泄。
- 药效与血浆浓度密切相关,常用药物相互作用有限,可固定剂量给药且无需治疗药物监测。
核心结论
- 阿哌沙班药代动力学在广泛患者人群中一致,与多数常用药物临床相关相互作用有限,可固定剂量使用而无需治疗药物监测。
研究设计与样本
- 综述汇总阿哌沙班的药代动力学、药效学、生物药剂学与药物相互作用特征,并讨论健康受试者与目标患者人群的群体药代动力学分析。
主要发现
- 绝对口服生物利用度约50%,食物对生物利用度无临床意义影响。
- 口服剂量至10mg时暴露呈剂量比例增加,给药后3-4小时达峰浓度,半衰期约12小时。
- 消除经代谢、胆汁排泄和直接肠道排泄等多途径,约27%总清除经肾排泄。
- 药效学效应与阿哌沙班血浆浓度密切相关。
临床怎么用
- 基于综述所述药代特征,临床可按固定剂量使用阿哌沙班而无需常规治疗药物监测。
- 食物不影响其生物利用度,服药不受进食限制(依据原文食物无临床意义影响)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis or pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism. The absolute oral bioavailability of apixaban is ~ 50%. Food does not have a clinically meaningful impact on the bioavailability. Apixaban exposure increases dose proportionally for oral doses up to 10 mg. Apixaban is rapidly absorbed, with maximum concentration occurring 3-4 h after oral administration, and has a half-life of approximately 12 h. Elimination occurs via multiple pathways including metabolism, biliary excretion, and direct intestinal excretion, with approximately 27% of total apixaban clearance occurring via renal excretion. The pharmacokinetics of apixaban are consistent across a broad range of patients, and apixaban has limited clinically relevant interactions with most commonly prescribed medications, allowing for fixed dosages without the need for therapeutic drug monitoring. The pharmacodynamic effect of apixaban is closely correlated with apixaban plasma concentration. This review provides a summary of the pharmacokinetic, pharmacodynamic, biopharmaceutical, and drug-drug interaction profiles of apixaban. Additionally, the population-pharmacokinetic analyses of apixaban in both healthy subjects and in the target patient populations are discussed.
引用
- Byon W, Garonzik S, Boyd RA, et al. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019. PMID: 31089975. doi:10.1007/s40262-019-00775-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。